Kernaussagen
- 1Patent expiry did what competition always does: imatinib prices fell >90% once multiple manufacturers entered most markets.
- 2Continuity was the entire clinical requirement — no dose was missed through the family's coverage transition.
- 3Treatment-free remission is possible for some CML patients, but only inside strict monitored protocols, never as a cost decision.
- 4Molecular monitoring (BCR-ABL transcript levels) is what makes any product change objectively verifiable in CML.
Fallüberblick
- Patientenprofil
- Composite profile — 11-year-old with chronic myeloid leukaemia
- Land
- Spain, with family originally from outside the EU
- Erkrankung
- Chronic myeloid leukaemia, chronic phase
- Medikament
- Imatinib 400 mg daily
Kosten im Westen
~$126,000 per year (branded reference)
Referenzalternative
~$1,440 per year reference
Wirkung
Indefinite therapy becomes sustainable
Auf dieser Seite
1A disease transformed by one molecule
Chronic myeloid leukaemia was, within living memory, a disease with a poor prognosis. The arrival of imatinib — a targeted inhibitor of the specific abnormal protein driving the disease — changed that fundamentally, with many patients achieving long-term disease control on continuing oral therapy.
The corollary is that therapy is typically indefinite. For a child diagnosed at eleven, the relevant time horizon is decades, and at branded pricing the lifetime figure becomes almost unreadable.
2The family's specific problem
The child's treatment was covered under the national system, but the family faced a period of transition in residency status during which coverage was uncertain. They needed to guarantee no interruption in therapy during that window.
In CML, treatment interruption risks loss of molecular response. Continuity was the entire clinical requirement.
3How continuity was secured
The paediatric haematology team treated this as a continuity-of-care problem rather than a purchasing problem, which reframed the options usefully.
- 1Confirmed the exact product, strength and daily dose in writing.
- 2Established the buffer supply needed to cover the coverage gap.
- 3Verified generic manufacturers with recognised regulatory approvals.
- 4Arranged continued molecular monitoring — BCR-ABL transcript levels — regardless of supply source.
- 5Documented every product and batch used, so any change in response could be investigated properly.
- 6Applied to a childhood cancer charity for interim support.
| Source | Annual cost | Notes |
|---|---|---|
| Branded reference | ~$126,000 | Pre-expiry list pricing basis |
| European generic | ~$3,600 | Post-patent competition |
| Indian generic reference | ~$1,440 | High-volume market pricing |
| National health coverage | $0 to patient | Where eligibility applies |
4Outcome
No dose was missed during the transition. Molecular monitoring showed the response was maintained throughout, and coverage resumed once residency was resolved.
The family's most useful decision was raising the coverage gap with the clinical team months in advance rather than weeks. Continuity planning is much easier with lead time.
5About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
Showing figures without a story leaves the real lesson out: these cases are about adherence that became possible again, monitoring that started up again, and rationing that stopped — not simply about a cheaper invoice.
Discuss any change of medicine, dose or brand with a licensed clinician before acting on anything on this page.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
Was der Jivan-Datensatz zeigt
- 27.5×
- durchschnittliche Preislücke Oncology
- 89.2%
- der Anker übersteigt 10×
- 129×
- größte dokumentierte Lücke
Across our Oncology anchors, 83 referenced molecules average a 27.5× price gap, 89.2% of them are at least 10× cheaper in India, and the widest documented comparison is Thalidomide at 129×. Targeted-therapy anchors show the steepest collapse after patent expiry of any therapy class in our data — a clear competition effect rather than a manufacturing difference.
Live berechnet aus 83 anchors
Häufige Fragen
Generic imatinib is approved in regulated markets on the basis of bioequivalence and is widely used. In CML, response is objectively measurable through molecular monitoring, which provides direct confirmation that therapy is working.
Treatment-free remission is possible for some patients with sustained deep molecular response, but only within strict protocols with intensive monitoring. It is never a decision to make for financial reasons.
Regular BCR-ABL transcript measurement to confirm molecular response, plus blood counts and clinical review. This monitoring is what makes any product change objectively verifiable.
Quellen und weiterführende Literatur
Jede sachliche Aussage oben ist zu einer öffentlichen Primärquelle rückverfolgbar. Wir zitieren Regulierer und Gesundheitsbehörden, keine Händler.
- 1Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)U.S. Food & Drug Administration
- 2Generic and Hybrid MedicinesEuropean Medicines Agency
- 3WHO Model List of Essential MedicinesWorld Health Organization
- 4MedlinePlus Drug InformationU.S. National Library of Medicine
Wie dieser Artikel entstand
Geschrieben und recherchiert
Pricing Research Editor, Jivan Editorial TeamRedaktionell geprüft
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Wichtiger medizinischer Hinweis
Ändern Sie Medikament, Dosis oder Hersteller nur nach Rücksprache mit einer approbierten Ärztin oder einem approbierten Arzt. Jivan liefert Bildungs- und Preisinformationen und ersetzt keine Diagnose oder Notfallversorgung.